No Data
Tigermed: voting results of the annual general meeting of shareholders in 2021, the first A-share shareholders' meeting in 2022 and the first H-share shareholders' meeting in 2022
Tigermed: notice of the 2021 Annual General meeting
Tigermed: annual report 2021
Tigermed: first quarterly report 2022
Tigermed: annual results announcement for the year ended December 31, 2021
Tigermed: the date of the board meeting
Nomura Adjusts Tigermed's Price Target to 147.33 Yuan From 154.89 Yuan, Keeps at Buy
05:42 AM EDT, 03/14/2022 (MT Newswires) -- Tigermed (SHE:300347) has an average rating of outperform and price targets ranging from 67 yuan to 236 yuan according to analysts polled by Capital IQ. (MT
Tigermed: the total transaction value of the first repurchase of 16600 shares is about 1.6348 million yuan.
Tigermed (300347) announced that on February 15, the company bought back 16600 shares of the company for the first time through a special securities account for share repurchase, accounting for 0.0019% of the company's current total share capital. The highest transaction price is 99.2 yuan per share, the lowest transaction price is 97.5 yuan per share, and the total transaction amount is 1634800.00 yuan (excluding transaction fees).
After the flash collapse! Changchun Hi-Tech once again fell by the limit, when will it stop falling?
Changchun high and new technology fell to the limit again after yesterday's flash fall, and as of press time, it was quoted at 204.84 yuan, down 10%, changed hands 0.73%, and the turnover was 554 million. The company responded that growth hormone products were included in the drug collection of Guangdong Province: no specific impact is expected at present. Data from yesterday's Dragon and Tiger list showed that Shenzhen shares sold 97.3 million yuan and bought 278 million yuan, while an institution sold 88.69 million yuan. In fact, outsiders have been paying more attention to whether Changchun's high-tech growth hormone products will be included in the collection. On August 16 last year, Zhang Deshen, secretary of Changchun High-tech Dong, was a guest at Securities.
[change of Rights and interests] Tigermed (03347.HK) was reduced by 15275 shares by Citigroup Inc
[Caihua Social News] according to the equity information of the Hong Kong Stock Exchange, Tigermed (03347.HK) was reduced by 15300 shares by Citigroup Inc at an average price of HK $94.8195 per share on January 13, involving a capital of about HK $1.4484 million. After the reduction, Citigroup Inc's latest number of shares is 7.376 million shares, with the proportion of shares reduced from 6.00% to 5.99%. (source: FinetAI)
Loading...